Zoheb B Kazi1, Sean N Prater1, Joyce A Kobori2, David Viskochil3, Carrie Bailey3, Renuka Gera4, David W Stockton5, Paul McIntosh6, Amy S Rosenberg7, Priya S Kishnani1. 1. Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA. 2. Department of Genetics, Kaiser Permanente, San Jose, California, USA. 3. Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA. 4. Department of Pediatrics/Human Development, Michigan State University, East Lansing, Michigan, USA. 5. Division of Genetic, Genomic and Metabolic Disorders, Departments of Pediatrics and Internal Medicine, Wayne State University and Children's Hospital of Michigan, Detroit, Michigan, USA. 6. School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA. 7. Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Enzyme replacement therapy (ERT) has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD), a rapidly progressive neuromuscular disorder. Yet marked interindividual variability in response to ERT, primarily attributable to the development of antibodies to ERT, remains an ongoing challenge. Immune tolerance to ongoing ERT has yet to be described in the setting of an entrenched immune response. METHODS: Three infantile Pompe patients who developed high and sustained rhGAA IgG antibody titers (HSAT) and received a bortezomib-based immune tolerance induction (ITI) regimen were included in the study and were followed longitudinally to monitor the long-term safety and efficacy. A trial to taper the ITI protocol was attempted to monitor if true immune tolerance was achieved. RESULTS: Bortezomib-based ITI protocol was safely tolerated and led to a significant decline in rhGAA antibody titers with concomitant sustained clinical improvement. Two of the 3 IPD patients were successfully weaned off all ITI protocol medications and continue to maintain low/no antibody titers. ITI protocol was significantly tapered in the third IPD patient. B cell recovery was observed in all 3 IPD patients. CONCLUSION: This is the first report to our knowledge on successful induction of long-term immune tolerance in patients with IPD and HSAT refractory to agents such as cyclophosphamide, rituximab, and methotrexate, based on an approach using the proteasome inhibitor bortezomib. As immune responses limit the efficacy and cost-effectiveness of therapy for many conditions, proteasome inhibitors may have new therapeutic applications. FUNDING: This research was supported by a grant from the Genzyme Corporation, a Sanofi Company (Cambridge, Massachusetts, USA), and in part by the Lysosomal Disease Network, a part of NIH Rare Diseases Clinical Research Network (RDCRN).
BACKGROUND: Enzyme replacement therapy (ERT) has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD), a rapidly progressive neuromuscular disorder. Yet marked interindividual variability in response to ERT, primarily attributable to the development of antibodies to ERT, remains an ongoing challenge. Immune tolerance to ongoing ERT has yet to be described in the setting of an entrenched immune response. METHODS: Three infantile Pompe patients who developed high and sustained rhGAA IgG antibody titers (HSAT) and received a bortezomib-based immune tolerance induction (ITI) regimen were included in the study and were followed longitudinally to monitor the long-term safety and efficacy. A trial to taper the ITI protocol was attempted to monitor if true immune tolerance was achieved. RESULTS:Bortezomib-based ITI protocol was safely tolerated and led to a significant decline in rhGAA antibody titers with concomitant sustained clinical improvement. Two of the 3 IPD patients were successfully weaned off all ITI protocol medications and continue to maintain low/no antibody titers. ITI protocol was significantly tapered in the third IPD patient. B cell recovery was observed in all 3 IPD patients. CONCLUSION: This is the first report to our knowledge on successful induction of long-term immune tolerance in patients with IPD and HSAT refractory to agents such as cyclophosphamide, rituximab, and methotrexate, based on an approach using the proteasome inhibitor bortezomib. As immune responses limit the efficacy and cost-effectiveness of therapy for many conditions, proteasome inhibitors may have new therapeutic applications. FUNDING: This research was supported by a grant from the Genzyme Corporation, a Sanofi Company (Cambridge, Massachusetts, USA), and in part by the Lysosomal Disease Network, a part of NIH Rare Diseases Clinical Research Network (RDCRN).
Authors: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245
Authors: P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith Journal: Neurology Date: 2006-12-06 Impact factor: 9.910
Authors: Priya Sunil Kishnani; Marc Nicolino; Thomas Voit; R Curtis Rogers; Anne Chun-Hui Tsai; John Waterson; Gail E Herman; Andreas Amalfitano; Beth L Thurberg; Susan Richards; Mark Davison; Deyanira Corzo; Y T Chen Journal: J Pediatr Date: 2006-07 Impact factor: 4.406
Authors: Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg Journal: Pediatrics Date: 2003-08 Impact factor: 7.124
Authors: Tracy E Hunley; Deyanira Corzo; Martha Dudek; Priya Kishnani; Andrea Amalfitano; Yuan-Tsong Chen; Susan M Richards; John A Phillips; Agnes B Fogo; George E Tiller Journal: Pediatrics Date: 2004-10 Impact factor: 7.124
Authors: Sarah P Young; Haoyue Zhang; Deyanira Corzo; Beth L Thurberg; Deeksha Bali; Priya S Kishnani; David S Millington Journal: Genet Med Date: 2009-07 Impact factor: 8.822
Authors: Marc Nicolino; Barry Byrne; J Edmund Wraith; Nancy Leslie; Hanna Mandel; David R Freyer; Georgianne L Arnold; Eniko K Pivnick; C J Ottinger; Peter H Robinson; John-Charles A Loo; Martin Smitka; Philip Jardine; Luciano Tatò; Brigitte Chabrol; Shawn McCandless; Shigemi Kimura; L Mehta; Deeksha Bali; Alison Skrinar; Claire Morgan; Lakshmi Rangachari; Deya Corzo; Priya S Kishnani Journal: Genet Med Date: 2009-03 Impact factor: 8.822
Authors: A S De Groot; Z B Kazi; R F Martin; F E Terry; A K Desai; W D Martin; P S Kishnani Journal: Clin Immunol Date: 2019-01-31 Impact factor: 3.969
Authors: Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; R Bradley Troxler; Raymond Y Wang; Omar A Abdul-Rahman; Pranoot Tanpaiboon; Nancy J Mendelsohn; Eli Herskovitz; David Kronn; Michal Inbar-Feigenberg; Catherine Ward-Melver; Michelle Polan; Punita Gupta; Amy S Rosenberg; Priya S Kishnani Journal: JCI Insight Date: 2017-08-17
Authors: Junjiang Sun; Wenwei Shao; Xiaojing Chen; Elizabeth P Merricks; Lauren Wimsey; Yasmina L Abajas; Glenn P Niemeyer; Clinton D Lothrop; Paul E Monahan; R Jude Samulski; Timothy C Nichols; Chengwen Li Journal: Mol Ther Methods Clin Dev Date: 2018-08-04 Impact factor: 6.698